The Role of Tissue Biopsy in the Management of Immune Checkpoint Inhibitor Toxicity

Authors:
Leslie A. Fecher Division of Hematology/Oncology,

Search for other papers by Leslie A. Fecher in
Current site
Google Scholar
PubMed
Close
 MD
,
Shrinivas Bishu Division of Gastroenterology, and

Search for other papers by Shrinivas Bishu in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert J. Fontana Division of Gastroenterology, and

Search for other papers by Robert J. Fontana in
Current site
Google Scholar
PubMed
Close
 MD
,
Salim S. Hayek Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan.

Search for other papers by Salim S. Hayek in
Current site
Google Scholar
PubMed
Close
 MD
, and
Bryan J. Schneider Division of Hematology/Oncology,

Search for other papers by Bryan J. Schneider in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Immune checkpoint inhibitors have revolutionized the treatment of cancer and are now omnipresent. However, immune-related adverse events can present with varying phenotypes and timing, which can pose diagnostic and therapeutic challenges for the treating oncologist as well as subspecialty consultants. Biopsies of affected organs may provide insight into biologic mechanisms as well as potentially guide management in certain circumstances.

Submitted December 20, 2021; accepted for publication February 23, 2022.

Disclosures: Dr. Fecher has disclosed participating in research for and serving as a principal investigator for Bristol-Myers Squibb, EMD Serono, Array, Pfizer, and Kartos; and serving as a consultant for Elsevier. The remaining authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Correspondence: Bryan J. Schneider, MD, Division of Hematology/Oncology, University of Michigan, C411MIB, 1500 East Medical Center Drive, SPC 5848, Ann Arbor, MI 48109-5848. Email: bryansch@med.umich.edu
  • Collapse
  • Expand
  • 1.

    Thompson JA, Schneider BJ, Brahmer J, et al. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 3.2021. Accessed December 19, 2021. To view the most recent version, visit NCCN.org

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Gong Z, Wang Y. Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review. JCO Oncol Pract 2020;16:453461.

  • 3.

    Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Sasson SC, Slevin SM, Cheung VTF, et al. Interferon-gamma-producing CD8+ tissue resident nemory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 2021;161:12291244.e9.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Luoma AM, Suo S, Williams HL, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 2020;182:655671.e22.

  • 6.

    Dougan M, Wang Y, Rubio-Tapia A, et al. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160:13841393.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. U.S. Department of Health and Human Services; 2017. Accessed December 19, 2021. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_50

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Mooradian MJ, Wang DY, Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020;8:e000451.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Peeraphatdit TB, Wang J, Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology 2020;72:315329.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Tsung I, Dolan R, Lao CD, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther 2019;50:800808.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med 2021;27:152164.

  • 13.

    De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68:11811190.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Johncilla M, Misdraji J, Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 2015;39:10751084.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018;31:965973.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Li M, Sack JS, Bell P, et al. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol 2021;7:17111714.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:16071616.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer 2018;125:150156.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Naidoo J, Wang X, Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 2017;35:709717.

  • 20.

    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158168.

  • 21.

    Atchley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer: real-world incidence, risk factors, and management practices across six health care centers in North Carolina. Chest 2021;160:731742.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Koelzer VH, Rothschild SI, Zihler D, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study. J Immunother Cancer 2016;4:13.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017;50:1700050.

  • 24.

    Larsen BT, Chae JM, Dixit AS, et al. Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol 2019;43:13311340.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Gettinger SN, Zhang X, Homer R, et al. Pneumonitis in non-small cell lung cancer (NSCLC) patient treated with programmed death (PD1) axis inhibitors [abstract]. J Clin Oncol 2016;34(Suppl):Abstratct 34.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Suresh K, Naidoo J, Zhong Q, et al. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Invest 2019;129:43054315.

  • 27.

    Pue CA, Pacht ER. Complications of fiberoptic bronchoscopy at a university hospital. Chest 1995;107:430432.

  • 28.

    Rubio-Infante N, Ramírez-Flores YA, Castillo EC, et al. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021;23:17391747.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 2018;19:15791589.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Lehmann LH, Cautela J, Palaskas N, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review. JAMA Cardiol 2021;6:13291337.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Power JR, Alexandre J, Choudhary A, et al. Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis. Circulation 2021;144:15211523.

  • 32.

    Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. J Am Coll Cardiol 2007;50:19141931.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Saraiva F, Matos V, Gonçalves L, et al. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant Proc 2011;43:19081912.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Yilmaz A, Kindermann I, Kindermann M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010;122:900909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation 2013;128:15311541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:10771084.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987;1:314.

  • 38.

    Champion SN, Stone JR. Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. Mod Pathol 2020;33:99108.

  • 39.

    Palaskas NL, Segura A, Lelenwa L, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail 2021;23:17251735.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Cortazar FB, Marrone KA, Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 2016;90:638647.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Mamlouk O, Selamet U, Machado S, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 2019;7:2.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Herrmann SM, Alexander MP, Romero MF, et al. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases. Kidney Med 2020;2:657662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Cortazar FB, Kibbelaar ZA, Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 2020;31:435446.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Wanchoo R, Karam S, Uppal NN, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 2017;45:160169.

  • 45.

    Herrmann SM, Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep 2020;5:11391148.

  • 46.

    Izzedine H, Mateus C, Boutros C, et al. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017;32:936942.

  • 47.

    Gallan AJ, Alexander E, Reid P, et al. Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors. Am J Kidney Dis 2019;74:853856.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009;361:211212.

  • 49.

    Dumoulin DW, Visser S, Cornelissen R, et al. Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC. J Thorac Oncol 2020;15:14721483.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Kumar V, Chaudhary N, Garg M, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 2017;8:49.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Ziemer M, Koukoulioti E, Simon JC, et al. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 2017;66:657659.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Qin Q, Patel VG, Wang B, et al. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors [abstract]. J Clin Oncol 2020;38(Suppl):Abstract e15160.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc 2006;63(Suppl 4):S1628.

  • 54.

    Boyum JH, Atwell TD, Schmit GD, et al. Incidence and risk factors for adverse events related to image-guided liver biopsy. Mayo Clin Proc 2016;91:329335.

  • 55.

    Sekiguchi M, Take M. World survey of catheter biopsy of the heart. In: Cardiomyopathy: Clinical, Pathological and Theoretical Aspects. Sekiguchi M, Olsen EG, eds. Baltimore, MD: University Park Press; 1980.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Atwell TD, Spanbauer JC, McMenomy BP, et al. The timing and presentation of major hemorrhage after 18,947 image-guided percutaneous biopsies. AJR Am J Roentgenol 2015;205:190195.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 3393 504 17
PDF Downloads 1647 177 17
EPUB Downloads 0 0 0